Education
About Us
Working with TipRanks
Follow Us
Fortress Biotech Inc (FBIO)
:FBIO
Top Page
Fortress Biotech
(NASDAQ:FBIO)
48Neutral
Fortress Biotech (FBIO) vs. S&P 500 (SPY)
Market Cap
$47.76M
Dividend YieldN/A
Average Volume (3M)345.25K
Price to Earnings (P/E)―
Beta (1Y)2.42
Revenue Growth-22.81%
EPS Growth86.68%
CountryUS
Employees186
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.27
Shares Outstanding27,604,935
10 Day Avg. Volume462,550
30 Day Avg. Volume345,252
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.59
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.00Price Target Upside887.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Fortress Biotech Business Overview & Revenue Model
Company DescriptionFortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National. The National segment consists of National Holdings Corporation, an independent brokerage company. The company was founded on June 28, 2006 in and is headquartered in New York, NY.
How the Company Makes MoneyFortress Biotech makes money through a multi-faceted revenue model that includes the acquisition and development of novel drugs, which are then commercialized either independently or through its network of partner companies. Key revenue streams include product sales, licensing agreements, royalties, and strategic partnerships. The company often collaborates with other biotech firms to co-develop and co-market therapies, thereby sharing costs and revenues. Additionally, Fortress Biotech may receive milestone payments and research funding from its partners, contributing to its overall earnings. These strategic collaborations and diversified product offerings allow the company to sustain and grow its revenue base.
Fortress Biotech Financial Statement Overview
Summary
Fortress Biotech faces significant financial challenges, with consistent losses and high leverage. Despite some revenue growth, the company's profitability and cash flow generation remain weak, posing risks to its financial health. Continued focus on improving operational efficiency and managing debt is crucial for future stability.Income Statement
Fortress Biotech has shown some revenue growth over the years, but continues to struggle with profitability. The TTM (Trailing-Twelve-Months) data reveals negative EBIT and net income margins, indicating ongoing challenges in achieving operational efficiency and profitability. The revenue growth rate from 2022 to 2023 was negative, suggesting a downturn in sales performance.45
Neutral
Balance Sheet
The company's balance sheet shows high leverage with a debt-to-equity ratio indicating significant reliance on debt financing. The declining equity ratio over the years reflects a weakening financial position. Return on equity is negative, pointing to profitability issues. Despite maintaining some cash reserves, the reduction in total assets and stockholders' equity suggests financial instability.40
Negative
Cash Flow
Cash flow analysis shows consistent negative operating and free cash flows, indicating substantial cash outflows from operations. However, there has been some improvement in free cash flow growth rate, supported by financing activities. The operating cash flow to net income ratio is unfavorable, reflecting the company's struggle to convert income into cash.50
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 62.50M | 84.51M | 75.74M | 68.79M | 45.60M | 36.63M | Gross Profit |
| 37.47M | 57.85M | 44.97M | 36.71M | 31.00M | 26.10M | EBIT |
| -106.11M | -142.34M | -202.26M | -179.00M | -94.27M | -110.82M | EBITDA |
| -107.42M | -133.64M | -190.47M | -142.25M | -87.82M | -85.16M | Net Income Common Stockholders |
| -50.83M | -60.64M | -213.91M | -164.83M | -102.98M | -51.81M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 83.11M | 80.93M | 178.27M | 305.74M | 233.35M | 136.86M | Total Assets |
| 140.99M | 167.53M | 294.30M | 396.50M | 328.83M | 226.42M | Total Debt |
| 79.50M | 88.59M | 127.34M | 74.98M | 89.08M | 115.14M | Net Debt |
| 13.99M | 7.67M | -50.92M | -230.77M | -144.28M | -21.72M | Total Liabilities |
| 121.25M | 165.94M | 244.28M | 170.63M | 131.84M | 153.89M | Stockholders Equity |
| 1.85M | 22.54M | 41.72M | 108.67M | 100.34M | 26.21M |
| Cash Flow | Free Cash Flow | ||||
| -102.28M | -136.32M | -182.46M | -132.89M | -90.85M | -104.36M | Operating Cash Flow |
| -102.22M | -128.22M | -179.40M | -116.54M | -83.68M | -94.96M | Investing Cash Flow |
| -63.00K | -2.10M | -22.93M | 40.51M | -7.16M | 20.10M | Financing Cash Flow |
| 88.45M | 32.74M | 75.32M | 148.99M | 172.41M | 146.71M |
Fortress Biotech Technical Analysis
Positive
1.62
Price Trends
1.81
Negative
1.82
Negative
1.84
Negative
Market Momentum
-0.03
Negative
55.37
Neutral
77.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBIO, the sentiment is Positive. The current price of 1.62 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.81, and below the 200-day MA of 1.84, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 55.37 is Neutral, neither overbought nor oversold. The STOCH value of 77.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FBIO.
Fortress Biotech Risk Analysis
Fortress Biotech disclosed 64 risk factors in its most recent earnings report. Fortress Biotech reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Fortress Biotech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $1.34B | ― | -4.86% | ― | 26.20% | -219.22% | |
60 Neutral | $1.34B | ― | -23.01% | ― | 168.06% | 44.66% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
48 Neutral | $47.76M | ― | -256.45% | ― | -22.81% | 86.68% | |
48 Neutral | $1.58B | ― | 18.68% | ― | 36.00% | 63.50% | |
42 Neutral | $241.55M | ― | -31.41% | ― | 389.82% | -22.66% | |
41 Neutral | $62.62M | ― | 41.08% | ― | -0.55% | 49.85% |
* Healthcare Sector Average
Performance Comparison
FBIO
Fortress Biotech
1.62
-0.06
-3.57%
BCRX
BioCryst
7.54
2.65
54.19%
XOMA
Xoma
20.27
-5.50
-21.34%
KPTI
Karyopharm Therapeutics
6.94
-13.16
-65.47%
ANIP
ANI Pharmaceuticals
61.46
-4.59
-6.95%
ARDX
Ardelyx
5.42
-2.61
-32.50%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.